成年人复发／难治性急性淋巴细胞白血病的研究进展  

Research progress of adult relapsed/refractory acute lymphoblastic leukemia

作　　者：宋洋 秘营昌 Song Yang, Mi Yingchang(Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China)

机构地区：[1]中国医学科学院北京协和医学院血液病医院血液学研究所,天津300020

出　　处：《国际输血及血液学杂志》2018年第2期180-184,F0003,共6页International Journal of Blood Transfusion and Hematology

基　　金：天津市基础重点项目（15JCZDJC36400）

摘　　要：急性淋巴细胞白血病（ALL）是一种由淋巴母细胞在造血和淋巴组织无限增殖所致的进行性恶性血液系统疾病。ALL成年患者的长期生存率较低，并且除了部分初治即确诊为难治性ALL患者外，30％-60％获得CR者最终进展为复发／难治性ALL病例。虽然以细胞毒药物为基础的传统治疗方案对于复发／难治性ALL患者的疗效不佳，但是包括单克隆抗体，嵌合抗原受体T细胞（CAR-T）等免疫治疗方法的广泛使用，使其预后得到显著提高。但是，对于复发／难治性ALL患者而言，异基因干细胞移植（allo-SCT）仍是其最终可能获得治愈的手段。Acute lymphoblastic leukemia unlimited proliferation of lymphoblastic cells in AI.L adult patients is low. In addition to some relapse and refractory （ALL） is a progressive hematologic malignancy caused by hematopoietic and lymphoid tissues. Long-term survival of refractory cases, 30%-60%CR patients eventually become the context of poor efficacy of traditional cytotoxic therapy,including monoclonal antibody and antigen used. The prognosis of patients with relapsed and refractory the end, allogeneic stem cell transplantation （allo-SCT） is refractory ALL patients. receptor T-cell ALI. have been the most likely drug-based regimen, immune （CAR-T）, has been widely significantly improved. But in chance to cure relapsed and

关 键 词：白血病 淋巴样 复发 难治性 干细胞移植 免疫疗法 

分 类 号：R733.71[医药卫生—肿瘤]